What are the clinical uses of intravenous magnesium sulfate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clinical Uses of Intravenous Magnesium Sulfate

Intravenous magnesium sulfate has four primary evidence-based indications: prevention and treatment of eclampsia in preeclampsia, treatment of torsades de pointes and drug-induced QT prolongation, management of digoxin toxicity with ventricular arrhythmias, and correction of hypomagnesemia.

Obstetric Indications

Preeclampsia and Eclampsia Prevention

MgSO4 is the definitive therapy for preventing eclamptic seizures, reducing seizure risk by approximately 50%—you need to treat 100 women to prevent one seizure 1. The ISSHP guidelines strongly recommend that all preeclamptic women in low- and middle-income countries receive MgSO4, while in high-resource settings with specialized centers, selective use based on severity markers is reasonable 1.

Dosing regimen 2:

  • Loading dose: 4-5 g IV over 3-4 minutes (diluted to 10-20% concentration), simultaneously with 10 g IM (5 g in each buttock)
  • Maintenance: 4-5 g IM every 4 hours into alternate buttocks, OR 1-2 g/hour continuous IV infusion
  • Target serum level: 6 mg/100 mL (optimal for seizure control)
  • Duration: Continue for 24 hours postpartum, though some evidence suggests stopping after 8 g total if given before delivery may be sufficient 1
  • Maximum daily dose: 30-40 g per 24 hours 2

Critical safety monitoring 2:

  • Patellar reflexes must remain present
  • Respiratory rate >12/minute
  • Urine output >25-30 mL/hour
  • In renal insufficiency: maximum 20 g/48 hours with frequent serum levels

Important caveat: Continuous maternal administration beyond 5-7 days can cause fetal abnormalities 2.

Cardiac Arrhythmia Indications

Torsades de Pointes and Drug-Induced QT Prolongation

For recurrent torsades de pointes with acquired QT prolongation, IV magnesium sulfate is the Class I recommended treatment, even when serum magnesium is normal 3. This represents a Class I, Level C-LD recommendation from the 2017 AHA/ACC/HRS guidelines.

Dosing for torsades 3:

  • Initial bolus: 1-2 g IV push
  • Repeated doses: Titrate to suppress ectopy and nonsustained VT episodes
  • Magnesium suppresses torsades without necessarily shortening QT interval
  • Combine with potassium repletion to ≥4.0-4.5 mmol/L (target 4.5-5.0 mmol/L) and magnesium to ≥2.0 mmol/L 3

If torsades persists despite magnesium, temporary pacing or isoproterenol infusion to increase heart rate is recommended 3.

Digoxin Toxicity with Ventricular Arrhythmias

IV magnesium is often administered when ventricular arrhythmias are present in digoxin toxicity 3. This is used as adjunctive therapy while the definitive treatment—digoxin-specific Fab antibodies—is being prepared for severe cases (digoxin >4 ng/mL with serious arrhythmias).

Magnesium Deficiency States

Hypomagnesemia Treatment

Mild deficiency 2:

  • 1 g (8.12 mEq) IM every 6 hours for 4 doses
  • Total: 32.5 mEq per 24 hours

Severe hypomagnesemia 2:

  • Up to 250 mg/kg (approximately 2 mEq/kg) IM over 4 hours if necessary
  • OR 5 g (40 mEq) added to 1 L D5W or normal saline, infused over 3 hours
  • Critical point: Must not exceed renal excretory capacity

Total Parenteral Nutrition

Maintenance requirements 2:

  • Adults: 8-24 mEq (1-3 g) daily
  • Infants: 2-10 mEq (0.25-1.25 g) daily

Other Potential Uses (Lower Quality Evidence)

Acute Asthma Exacerbations

Recent 2025 meta-analysis shows IV MgSO4 as adjunct therapy significantly improves peak expiratory flow at 45 minutes (MD 18.50,95% CI 6.36-30.65) and reduces hospital admission rates (OR 0.45,95% CI 0.23-0.88) 4. However, this is not for routine use—reserve for severe cases refractory to first-line bronchodilators and corticosteroids 5.

Dosing for asthma 2:

  • 3-4 g (30-40 mL of 10% solution) IV over 30 seconds with extreme caution
  • Only if simpler measures have failed and no myocardial damage

Other Labeled Indications

The FDA label includes 2:

  • Barium poisoning: 1-2 g IV to counteract muscle-stimulating effects
  • Seizures (epilepsy, glomerulonephritis, hypothyroidism): 1 g IM or IV
  • Paroxysmal atrial tachycardia: 3-4 g IV over 30 seconds (only if simpler measures failed, no myocardial damage)
  • Cerebral edema reduction: 2.5 g IV

Administration and Safety Considerations

Rate of administration 2:

  • Generally should not exceed 150 mg/minute (1.5 mL of 10% solution)
  • Exception: severe eclampsia with active seizures
  • Must dilute to ≤20% concentration for IV infusion

Drug incompatibilities 2:

  • May precipitate with various solutions
  • Reduces antibiotic activity of streptomycin, tetracycline, and tobramycin when given together

Toxicity signs 3:

  • Areflexia progressing to respiratory depression at high serum concentrations
  • Risk is very small with typical doses (1-2 g) for torsades de pointes

Common pitfall: The most frequent error is failing to monitor patellar reflexes, respiratory rate, and urine output during prolonged infusions in preeclampsia. Loss of reflexes is the earliest sign of toxicity and mandates immediate cessation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.